ISSCR: The Manufacturing, Engineering and Regulation of Pluripotent Stem Cell-Derived Therapies

As more stem cell discoveries are translated, the development of products based on these discoveries will depend on solving manufacturing challenges, including the scale-up or scale-out of products to achieve commercial quantities and qualities.

This four-part meeting series is aimed at addressing these manufacturing and regulatory challenges to bring promising new cell therapies to the clinic.

Dr Moira François, Senior Scientist

Scale-up Manufacturing of Pluripotent Stem Cell Products


  • Marina Goldfeld, MA, BlueRock Therapeutics, USA
  • Moira Francois, PhD, Cell and Gene Therapy Catapult, UK
  • Stefan Braam, PhD, NCarida, Belgium


Dr Jacqueline Barry, Chief Clinical Officer

Navigating the Regulatory Environment: International Regulations for Pluripotent Derived Products


  • Jacqueline Barry, PhD, Cell and Gene Therapy Catapult, UK
  • Fumihito Takanashi, Ministry of Health, Labour and Welfare, Japan
  • Pete Coffey, PhD, UC Santa Barbara, USA and UCL, UK

Tuesday 1 June 2021, 15:00-16:30 BST 

Register here and view on demand!


  • 📣CGTC announces AAV reference material will be produced at the CGTC Braintree in collaboration with . F… 20 hours 58 sec ago

Discover who we are